CTXR: Citius Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 15.90
Enterprise Value ($M) 18.31
Book Value ($M) 68.92
Book Value / Share 8.02
Price / Book 0.23
NCAV ($M) -33.46
NCAV / Share -3.89
Price / NCAV -0.48

Profitability (mra)
Return on Invested Capital (ROIC) -0.57
Return on Assets (ROA) -0.41
Return on Equity (ROE) -0.46

Liquidity (mrq)
Quick Ratio 0.09
Current Ratio 0.41

Balance Sheet (mrq) ($M)
Current Assets 18.33
Assets 120.70
Liabilities 51.78
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -42.00
Net Income -39.14
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -28.20
Cash from Investing -5.00
Cash from Financing 9.97

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
11-27 13D/A Mazur Leonard L 9.30 -95.83
05-08 13G/A BlackRock, Inc. 4.80 1.99

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2024 ☐ TRANSITION REPO
2025-01-27 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2024 ☐ TRANSITION REP
2024-12-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECT
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT P
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 23,883 126,702 18.85
2025-02-20 146,886 442,230 33.21
2025-02-19 412,452 1,344,427 30.68
2025-02-18 39,840 150,299 26.51

(click for more detail)

Similar Companies
CRVO – CervoMed Inc. CSBR – Champions Oncology, Inc.
CSCI – COSCIENS Biopharma Inc. CUE – Cue Biopharma, Inc.
CVKD – Cadrenal Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io



This entry was posted in . Bookmark the permalink.